To restore efficacy (≥95% infection-reduction) to drugs against resistant infections (now, posing a bigger medical challenge, globally, than even HIV/AIDS), Cotrimoxazole was formulated with a synthetic Aluminum-magn...To restore efficacy (≥95% infection-reduction) to drugs against resistant infections (now, posing a bigger medical challenge, globally, than even HIV/AIDS), Cotrimoxazole was formulated with a synthetic Aluminum-magnesium silicate (Medicinal mineral which molecules are made of Nanoparticles, that is already in use as pharmaceutical-stabilizing agent) and used with antioxidants to treat Cotrimoxazole-resistant Salmonella pulorum infected chicks. Chick-groups A, B and C were fed antioxidants-fortified feed while groups D, E, F, G and H were not. The treatment-groups and their Cotrimoxazole doses/formulations were: A and D (100%/MSAMS-Cotrimoxazole);B and E (75%/MSAMS-Cotrimoxazole);C and F (50%/MSAMS-Cotrimoxazole) and G (100%/Cotrimoxazole). Infection-reductions (96.23% and 94.98%) of the groups of 75%/MSAMS-Cotrimoxazole/antioxidants and 75%/MSAMS-Cotrimoxazole were significantly (P ≤ 0.05) better than 76.99% (100%/Cotrimoxazole);10.04% (50%/MSAMS-Cotrimoxazole/antioxidants);1.60% (50%/MSAMS-Cotrimoxazole);−212.60% (100%/MSAMS-Cotrimoxazole/antioxidants) and −230.96% (100%/MSAMS-Cotrimoxazole).展开更多
文摘To restore efficacy (≥95% infection-reduction) to drugs against resistant infections (now, posing a bigger medical challenge, globally, than even HIV/AIDS), Cotrimoxazole was formulated with a synthetic Aluminum-magnesium silicate (Medicinal mineral which molecules are made of Nanoparticles, that is already in use as pharmaceutical-stabilizing agent) and used with antioxidants to treat Cotrimoxazole-resistant Salmonella pulorum infected chicks. Chick-groups A, B and C were fed antioxidants-fortified feed while groups D, E, F, G and H were not. The treatment-groups and their Cotrimoxazole doses/formulations were: A and D (100%/MSAMS-Cotrimoxazole);B and E (75%/MSAMS-Cotrimoxazole);C and F (50%/MSAMS-Cotrimoxazole) and G (100%/Cotrimoxazole). Infection-reductions (96.23% and 94.98%) of the groups of 75%/MSAMS-Cotrimoxazole/antioxidants and 75%/MSAMS-Cotrimoxazole were significantly (P ≤ 0.05) better than 76.99% (100%/Cotrimoxazole);10.04% (50%/MSAMS-Cotrimoxazole/antioxidants);1.60% (50%/MSAMS-Cotrimoxazole);−212.60% (100%/MSAMS-Cotrimoxazole/antioxidants) and −230.96% (100%/MSAMS-Cotrimoxazole).
